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Effects of the glutamate carboxypeptidase II (GCP2 1561CT) is even more pronounced in patients with chronic kidney
and reduced folate carrier (RFC1 80GA) allelic variants on disease on renal replacement therapy due to an altered
folate and total homocysteine levels in kidney transplant pa- homocysteine metabolism in such patients. [2] Over thetients.
past decade, several contributions have shown that ge-Background. The effect of the glutamate carboxypeptidase
netic polymorphisms might determine plasma tHcy lev-II GCP2 1561CT and the reduced folate carrier 1 RFC1
80GA polymorphisms on folate and total homocysteine els, either directly, or by affecting plasma folate levels.
(tHcy) plasma levels of kidney transplant patients are un- Mutations of the 5,10-methylenetetrahydrofolate reduc-
known. tase gene (MTHFR) have been studied extensively in aMethods. In a cross-sectional study of 730 kidney allograft
variety of populations and found to be associated with lowrecipients, GCP2 1561CT, RFC1 80GA, folate, and tHcy
folate levels and elevated tHcy plasma concentrationsplasma levels were analyzed using linear regression models
that allowed dependent covariates to follow a gamma distribu- [3]. More recently, two more polymorphisms have been
tion for univariate and multivariate analyses. discovered and hypothesized to influence tHcy plasma
Results. The allele frequency for GCP2 1561CT was 0.05,
levels: a 80GA exchange within the reduced folateand 0.43 for RFC1 80GA. Heterozygosity or homozygosity
carrier 1 gene (RFC1; HUGO gene symbol: SLC19A1;for GCP2 1561CT was associated with higher folate plasma
levels compared to patients without mutation (P  0.0001), solute carrier family 19, member 1) [4] and a 1561CT
while RFC1 80GA showed no influence. Multiple testing, transition of the glutamate carboxypeptidase II gene
also including MTHFR 677CT and MTHFR 1298AC, re- (GCP2: HUGO gene symbol: FOLH1; folate hydrolase 1)
vealed no interaction between the different genotypes and
[5]. The GCP2 1561CT mutation (H475Y) is locatedthe folate plasma concentration. Neither GCP2 1561CT nor
in exon 13 at the putative catalytic domain of the enzymeRFC1 80GA showed an association with tHcy plasma levels.
Conclusion. We conclude that GCP2 1561CT is associated and is associated with a 53% reduction of enzyme aciti-
with elevated folate levels. GCP2 1561CT and RFC1 80GA vity [5]. RFC1 80GA (R27H) occurs in exon 2 [4]. The
are no major determinants of tHcy plasma levels in kidney functional consequence of this polymorphism on the en-transplant patients.
coded protein is currently unknown.
The RFC1 gene product consists of 591 amino acid
residues with a predicted molecular mass of 65 kD and
Elevated plasma levels of total homocysteine (tHcy)
is termed human folate transporter (FOLT). Alternativeare associated with several adverse outcomes such as
titles and symbols are placental folate transporter 1; re-cardiovascular disease or neural tube defects in the gen-
duced folate carrier protein (RFC); and intestinal folateeral population [1]. The relevance of tHcy as a risk factor
carrier (IFC-1), which belongs to the SLC19A family of
transporters. The human FOLT is an integral membrane
protein. Transfection experiments with human RFC1Key words: GCP, RFC1, genetic polymorphism, mutation, folate, homo-
cysteine, kidney transplants. cDNAs revealed an increased uptake of 5-methyltetra-
hydrofolate [6] and 5-methyltetrahydrofolic acid [7],Received for publication December 6, 2002
suggesting involvement of the RFC1 gene product inand in revised form January 20, 2003
Accepted for publication February 3, 2003 internalization of folates into cells. In mice, a 58 kD
protein has been detected in the brush-border membrane 2003 by the International Society of Nephrology
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Table 1. Characteristics of 730 kidney graft recipientsof the intestine, which mediates intestinal folate trans-
port [8]. Furthermore, the folate transporter is possibly Variable Mean (SD) or %
important for the development of embryos, providing Age years 51.8 (13.1)
Gender female/male 292/438the folate transport across the placenta [9].
Body mass index kg/m2 25.4 (4.3)The GCP2 gene product consists of 750 amino acid
Estimated glomerular filtration rate mL/min 56.0 (20.1)
residues with an apparent molecular weight of 100 kD and Time since transplantation years 5.0 (4.1)
is termed folylpoly--glutamate carboxypetidase (FGCP).
Alternative titles and symbols are prostate-specific mem-
brane antigen (PSM); N-acetylated--linked acidic dipep-
tidase (NAALADase); folate hydrolase 1 (FOLH) [10]. for isolation of DNA were snap-frozen and stored at
70C. Plasma concentrations of tHcy (free plus protein-Folylpoly--glutamate carboxypetidase is an exopepti-
dase that is anchored to the apical brush-border mem- bound Hcy) [14] were determined by automated high-
performance liquid chromatography (HPLC) with re-brane and shows folate hydrolase and N-acetylated--
linked acidic dipeptidase activity. Folylpoly--glutamate versed-phase separation and fluorescence detection using
tri-n-butylphosphine as a reducing agent. Hyperhomo-carboxypetidase hydrolyses the terminal glutamate resi-
dues of dietary folylpoly--glutamates before absorp- cysteinemia was defined as tHcy levels above 15 mol/L
[14]. Intra-assay variability was between 1.4% and 1.7%tion. Thereafter, the monoglutamyl folate derivatives are
transported through the membrane via the folate trans- and interassay variability was between 1.5% and 1.9% for
tHcy concentrations of 15.9 and 6.9 mol/L, respectively.porter. Therefore, folylpoly--glutamate carboxypetidase
possibly regulates the availability of dietary folates [11]. Folate and vitamin B12 plasma levels were measured with
a radioassay (SimulTRAC-SNB, ICN Pharmaceuticals,The effect of GCP2 1561CT and RFC1 80GA on
tHcy and folate plasma level has only been studied in a Inc., Costa Mesa, CA, USA). Folate deficiency was de-
fined as a plasma concentration of less than 3.4 nmol/L,limited way, and the results are conflicting [12]. It was
the purpose of this study to describe the respective fre- and vitamin B12 deficiency was defined as a plasma con-
centration of less than 118 pmol/L, respectively. In-quencies of the GCP2 1561CT and the RFC1 80GA
allelic variants in a large cohort of patients with a func- terassay variability was 4% to 5% for folate measure-
ments and 4% to 6% for vitamin B12 levels. The creatininetioning kidney transplant and to test the hypothesis
whether these genetic characteristics were independently clearance was calculated using the equation of Cockcroft
and Gault [15].associated with folate or tHcy plasma levels. Further-
more, we sought to test interactions among the various RFC1 80GA was analyzed by restriction fragment
length polymorphism (RFLP) analysis of a 230 bp poly-allelic variants of the MTHFR, GCP2 and RFC1 genes
on folate and tHcy plasma levels. merase chain reaction (PCR) product that had been am-
plified with the primer pair RFC1 (5	-AGTGTCA
CCTTCGTCCC-3	; nucleotide 51–70, GenBank acces-
METHODS
sion number: U19720) and RFC2 (5	-TCCCGCGTGAAG
Study population TTCTTG-3	; nucleotide 263–280, GenBank accession
number: U19720). In the presence of the G allele, cleav-To assess the association between folate and tHcy
plasma levels, and RFC1 and GCP2 genotype status, we age with Cfo I produced three fragments of 125 bp, 37
bp, and 68 bp. The mutant A allele diminished a restric-conducted a cross-sectional study of 733 kidney allograft
recipients who received routine follow-up at our institu- tion site resulting in two fragments of 162 bp and 68
bp, respectively. The RFLP system for determination oftion. The detailed rules for study inclusion have been
published elsewhere [13]. Material for genetic analysis GCP2 1561CT included GCP1 (5	-GGTGAGAATG
ATGGACTTTAC-3	; nucleotide 46235–46255, GenBankwas unavailable for three individuals, which left a final
study population of 730 patients. None of the patients accession number: AF007544) and GCP2 (5	-CTTTG
AGCTCAGTTTCACTG-3	; nucleotide 46713–46732,received routine folic acid or vitamin B supplementation.
Important patient characteristics are shown in Table 1. GenBank accession number: AF007544) producing a 498
bp fragment that remained uncleaved by Acc I in theThe Institutional Review Board at the University of Vi-
enna gave study approval. All patients provided written presence of the C allele. The mutant T allele was cut by
Acc I into two fragments of 218 bp and 280 bp. Identifi-informed consent according to the Declaration of Hel-
sinki and the Austrian Law on Gene Technology. cation of the 677CT transition and of the 1298AC
transversion in MTHFR was performed by RFLP [16, 17].
Biochemical methods
Statistical analysesFasting citrated blood was immediately placed on ice,
and centrifuged at 2000 
 g at 4C (20 minutes) within The SAS for Windows (release 8.2) statistical software
was used for all analyses (SAS Institute, Inc., Cary, NC).60 minutes. Plasma aliquots and 500 L of citrated blood
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Table 4. Plasma folate and total homocysteine (tHcy) levels of 730Table 2. Vitamin status and total homocysteine (tHcy) plasma levels
of 730 kidney graft recipients kidney graft recipients according to RFC1 genotypes (meanSD)
RFC1 80GA genotypeMedian (25th/75th percentile)
GG GA AAPlasma vitamin B12 pmol/L 220 (170/308)
Plasma folate nmol/L 13.0 (10.0/16.9)
Number 243 352 135Plasma tHcy lmol/L 15.0 (11.9/19.8)
Plasma folate nmol/L 15.216 14.811.9 14.46.8
Plasma tHcy lmol/L 17.710.2 16.88.3 16.76.8
Table 3. Plasma folate and total homocysteine (tHcy) levels of 730
kidney graft recipients according to GCP2 genotypes (meanSD)
Table 5. Plasma folate and total homocysteine (tHcy) levels
GCP2 1561CT genotype of 730 kidney graft recipients according to MTHFR 677
genotypes (meanSD)CC CT TT
MTHFR 677CT genotypeNumber 654 74 2
Plasma folate nmol/L 14.713.2 15.67.1 24.712.8 CC CT TT
Plasma tHcy lmol/L 17.08.6 17.610.6 13.54.9
Number 344 307 79
Plasma folate nmol/L 15.36.3 15.217.8 11.78.6
Plasma tHcy lmol/L 15.87.1 17.17.9 22.514.7
We described important patient characteristics using
mean values and standard deviations for continuous vari-
ables and percentages for categorical variables. As the patients who were homozygous. All two-way interactions
distribution of plasma tHcy and folate levels was found between these dummy covariates were then tested for
to be skewed to the right, and therefore nonnormally significance. However, such an approach raises a multiple-
distributed, we used a special case of general linear mod-
testing problem, where some interactions will be foundels for all advanced analyses. The link function was cho-
significant by chance alone. Therefore, we used the ap-sen to be linear and spread was determined to follow a
proach described by Bonferroni to adjust the appropriategamma distribution (in SAS: PROC GENMOD, LINK
significance threshold ( level) for multiple testing [21].IDENTITY, DISTGAMMA). Such an approach pro-
vides unbiased estimates of effect for positively skewed
data without the need to conduct data transformation
RESULTS(e.g., to a logarithmic scale) [18, 19]. We used such mod-
Patients, vitamin status, and genotypesels both for univariate and multivariate analyses. One set
of analyses used plasma level of folate as the dependent The characteristics of all study participants are indi-
covariate, a second set modeled plasma tHcy concentra- cated in Table 1. The mean age in the cohort was 51.8
tion. Independent covariates included patient age (in years, 60% were male, and more than half of the patients
decades), gender, time since kidney transplantation (2 were obese or overweight (i.e., BMI 25 kg/m2). Table
vs. 2 years), and categories of underlying kidney dis- 2 depicts vitamin status and plasma tHcy levels of all
ease (diabetic nephropathy, glomerulonephritis, intersti- 730 kidney graft recipients. Exactly half of the patients
tial nephritis, polycystic kidney disease, miscellaneous had elevated tHcy (15 mol/L), only two patients
other defined, and kidney disease not otherwise defined). (0.3%) were below normal for plasma folate (3.4
We calculated each patient’s body mass index (BMI), nmol/L), and 66 patients (9.0%) had vitamin B12 levelscategorized in quintiles as the weight in kilograms di-
below the normal threshold (118 pmol/L).
vided by the squared height in meters and defined
The allele frequency of GCP2 1561CT was 0.05;quintiles of the plasma levels of folate and vitamin B12, 74 patients (study population prevalence 9.8%) wererespectively. For each patient, we estimated the creati-
heterozygous and two patients (0.3%) were homozygousnine clearance/glomerular filtration rate (GFR) using
for the mutation (Table 3). Because of the small numberthe Cockcroft-Gault approximation [15] and then staged
of homozygous patients, we combined those with therenal function in accordance with the recent guidelines
heterozygous patients for further analysis. The allele fre-of the National Kidney Foundation (NKF) (90, 60 to
quency of RFC1 80GA was 0.43; 352 patients (48.2%)90, 30 to 60, 30mL/min/1.73 m2) [20]. We created
were heterozygous and 135 patients (18.5%) were homo-dummy covariates for all allelic combinations of nucleo-
zygous for this variant (Table 4). The allele frequencytides 677 and 1298 of MTHFR, as well as for heterozygos-
of MTHFR 677CT was 0.32; 307 patients (42.1%) wereity and homozygosity of RFC1 80GA. Patients with
heterozygous and 79 patients (10.8%) were homozygousany mutation for the GCP2 gene at nucleotide 1561 were
put into one single category because there were only two for this variant (Table 5).
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Table 6. Estimated univariate and multivariate linear associations between genotypes and plasma folate (FA) levels
Univariate results Multivariate resultsa
Covariate Estimate FA in nmol/L 95% CI P value Estimate FA in nmol/L 95% CI P value
RFC1 genotypes
80GG — (Referent) — — (Referent) —
80GA 0.46 (1.62; 0.71) 0.443 0.32 (1.40; 0.76) 0.560
80AA 0.77 (2.24; 0.70) 0.304 0.08 (1.42; 1.26) 0.907
GCP2 genotypes
1561CC — (Referent) — — (Referent) —
1561CT or 1561TT 1.09 (0.68; 2.87) 0.226 2.01 (0.36; 3.65) 0.017
MTHFR genotypes
677CC/1298AA — (Referent) — — (Referent) —
677CC/1298AC 1.39 (3.24; 0.47) 0.143 1.05 (2.80; 0.70) 0.241
677CC/1298CC 0.03 (2.40; 2.35) 0.983 0.08 (2.32; 2.17) 0.948
677CT/1298AA 0.48 (2.43; 1.46) 0.626 0.49 (2.32; 1.34) 0.597
677CT/1298AC 1.30 (3.22; 0.62) 0.185 2.15 (3.93; 0.38) 0.018
677TT/1298AA 4.40 (6.38; 2.42) 0.0001 5.19 (7.06; 3.32) 0.0001
a All multivariate models simultaneously account for age, gender, body mass index, estimated glomerular filtration rate, plasma levels of vitamin B12, time since
transplantation, underlying kidney disease, and all genotypes of MTHFR, RFC1, and GCP2
Effect of GCP2 and RFC1 genotypes on plasma Effect of GCP2 and RFC1 genotypes on plasma
tHcy concentrationsfolate concentrations
Mean plasma levels of folate stratified by GCP2, Mean tHcy plasma levels according to GCP2, RFC1,
and MTHFR 677 genotypes are indicated in Tables 3,RFC1, and MTHFR 677 genotypes are shown in Tables
3, 4, and 5. We tested whether GCP2 or RFC1 were 4, and 5. When testing whether GCP2 1561CT or RFC1
associated with folate plasma levels using general linear 80GA were associated with tHcy plasma levels in re-
models. In univariate analyses, we did not find any associ- gression models, we did not detect any significant associ-
ations between the allelic variants of the RFC1 or GCP2 ations between any of the allelic variants and tHcy plasma
genes and plasma folate levels (Table 6). However, in levels both in univariate and in multivariate analyses
a multivariate model controlling for age, gender, renal (Table 7).
function, BMI, underlying renal disease, time since trans- When testing for combined effects of various allelic
plantation, and indicators for allelic status of MTHFR variants of MTHFR, RFC1, and GCP2 on tHcy, we again
677CT and 1298AC, we found that individuals with found two specific combinations to be significant before
the heterozygous or homozygous variants of the GCP2 adjustment for multiple testing: patients who had any
gene had a plasma folate concentration that was, on mutation of the GCP2 gene and were compound-hetero-
average, 2.01 nmol/L higher compared to patients with zygous for both MTHFR polymorphisms or homozygous
the GCP2 wild-type sequence (95% CI 0.36 to 3.65; P  for the MTHFR 1298AC mutation. As before, neither
0.012). Plasma folate levels among RFC1 allelic variants of the interactions remained significant after Bonferroni
did not differ in multivariate models (Table 6). adjustment [21].
When testing for combined effects of various allelic
variants of the MTHFR, RFC1, and GCP2 genes on
DISCUSSIONplasma folate (i.e., effect modification), we found two
In this study of 730 kidney transplant recipients, wespecific combinations to be of potential relevance. Pa-
analyzed whether allelic variants of two recently discov-tients who had any mutation of the GCP2 gene and were
ered genes, RFC1 and GCP2, were associated withheterozygous in either the MTHFR gene at nucleotide
plasma levels of folate and tHcy. This population is the677 (N 9; effect estimate of the interaction term5.08
largest thus far to be studied with regard to this specificnmol/L; 95% CI9.64;0.53; non-Bonferroni adjusted,
research question. Using general linear models and ac-P 0.03) or the MTHFR nucleotide 1298 (N 21; effect
counting for the skewed distribution of the outcomesestimate of the interaction term 3.95 nmol/L; 95% CI
variables we did not find any associations between RFC17.51;0.39; non-Bonferroni adjusted, P 0.03). These
genotype and plasma folate or tHcy, respectively. Thesefindings would indicate that the association found be-
findings arose from multivariate models that accountedtween nonhomozygosity in the GCP2 gene and elevated
for important potential confounders and predictors offolate was not present in patients who were heterozygous
the outcomes.for either of the two polymorphisms of MTHFR under
Similarly, we could not detect an association betweenstudy. However, using Bonferroni’s adjustment for mul-
plasma tHcy levels and either hetero- or homozygositytiple testing, we found that neither of the interactions
remained significant [21]. of the GCP2 1561CT mutation. However, plasma fo-
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Table 7. Estimated univariate and multivariate linear associations between genotypes and plasma total homocysteine (tHcy) levels
Univariate results Multivariate resultsa
Covariate Estimate tHcy in lmol/L 95% CI P value Estimate tHcy in lmol/L 95% CI P value
RFC1 genotypes
80GG (1.0) (Referent) — (1.0) (Referent) —
80GA 0.87 (2.04; 0.29) 0.142 0.06 (0.77; 0.88) 0.890
80AA 0.93 (2.41; 0.56) 0.221 0.33 (1.36; 0.69) 0.523
GCP2 genotypes
1561CC (1.0) (Referent) — (1.0) (Referent) —
1561CT or 1561TT 0.45 (1.26; 2.16) 0.609 0.11 (1.08; 1.29) 0.860
MTHFR genotypes
677CC/1298AA (1.0) (Referent) — (1.0) (Referent) —
677CC/1298AC 1.27 (0.27; 2.82) 0.106 0.37 (0.75; 1.49) 0.518
677CC/1298CC 1.56 (0.43; 3.55) 0.123 0.74 (0.73; 2.22) 0.323
677CT/1298AA 2.39 (0.75; 4.04) 0.004 0.91 (0.30; 2.12) 0.142
677CT/1298AC 2.10 (0.46; 3.74) 0.012 0.87 (0.33; 2.07) 0.154
677TT/1298AA 7.63 (5.30; 9.97) 0.0001 3.65 (1.84; 5.45) 0.0001
a All multivariate models simultaneously account for age, gender, body mass index, estimated glomerular filtration rate, plasma levels of folate, plasma levels of
vitamin B12, time since transplantation, underlying kidney disease, and all genotypes of MTHFR, RFC1, and GCP2
late was found to be elevated in patients with these plasma levels among dialysis patients carrying a mutated
T allele [22]. Similar to the present results, there was noallelic variants compared to individuals without mutation
(effect estimate 2.01 nmol/L; 95% CI 0.36 to 3.65; P  effect of GCP2 variants on homocysteine metabolism of
dialysis patients in a multivariate analysis after control-0.017).
Regarding the RFC1 allelic variants, these findings are ling for some of the most important modifiers of the
tHcy plasma level [22]. Vargas-Martinez et al [23] studiedconsistent with the existing literature. Fo¨dinger et al [22]
showed no major effect of RFC1 80GA on tHcy or folate the associations between GCP2 variants, and folate sta-
tus and tHcy levels. In participants from the Framinghamconcentrations in a cross-sectional group of 120 chronic
dialysis patients. The RFC1 80GA variant did not dem- Offspring Study, they found GCP2 1561CT to be associ-
ated with elevated plasma folate levels, but without effectonstrate any association with folate status or tHcy plasma
concentration among 169 French healthy adults, either on tHcy levels. We confirm these findings in renal trans-
plant patients.[4]. In this study, however, Chango et al [4] showed that
the RFC1 80GG/MTHFR 677TT genotype was associ- We did not find any interactions on folate or tHcy
plasma levels among the allelic variants under study afterated with moderately higher tHcy plasma concentrations
as compared to 80GG/677CC or 80GG/677CT genotype Bonferroni adjustment for multiple testing. However,
the present example illustrates how failure to account forpatients. Subjects with 80AA/677CT genotype showed
higher plasma folate levels as compared to 80GG/677CT multiple comparisons may lead to erroneous conclusions,
especially in genetic studies where multiple comparisonspatients. There was no other effect of the RFC1 polymor-
phism on plasma or red blood cell folate levels as mea- are often inevitable [21].
While not the centerpiece of the study, we confirmedsured by a microbiologic assay.
Devlin et al [5] found low levels of serum folate and that homozygosity for MTHFR 677CT was the most im-
portant genetic correlate of decreased plasma folate (bothelevated homocysteine to be related to the 1561CT
polymorphism of GCP2 (H475Y) in 75 healthy Cauca- by significance and effect size), while compound heterozy-
gosity for both the MTHFR 677T and 1298C also seemedsians. [5] This observation was explained by a dimin-
ished activity of folypoly--glutamate carboxypeptidase to be modestly associated with lower plasma folate levels
(Table 6). Clearly, homozygosity for MTHFR 677CTin H475Y-transfected COS-7 cells. Thus, this study sug-
gested that the presence of the mutated GCP2 allele remained the only genetic variant described thus far to
be independently associated with increased tHcy (Table 7).impaired the intestinal absorption of dietary folates, re-
sulting in relatively low blood folate levels and conse- The present study has certain limitations. Findings
from a population of renal transplant patients may not bequent hyperhomocysteinemia. Our findings that the
1561CT mutation of the GCP2 gene was associated representative of other populations. The cross-sectional
design makes it possible that time-related biases are op-with higher plasma folate levels in multivariate analyses
are at odds with the observations of Devlin et al [5], erational, most importantly survival bias. Certain geno-
type combinations might affect eligibility for transplanta-and in better congruence with a previous study at our
institution that showed similar plasma folate levels, but tion or patient survival so that such patients are less
likely to be represented in the analysis. However, suchsomewhat higher red blood cell folate and lower tHcy
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